# Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM

> **NCT06515262** · NA · RECRUITING · sponsor: **920th Hospital of Joint Logistics Support Force of People's Liberation Army of China** · enrollment: 10 (estimated)

## Conditions studied

- Relapsed/Refractory Multiple Myeloma

## Interventions

- **BIOLOGICAL:** Anti-BCMA-GPRC5D CAR-T cells infusion

## Key facts

- **NCT ID:** NCT06515262
- **Lead sponsor:** 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2026-11
- **Final completion:** 2026-12
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2024-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06515262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06515262, "Safety and Efficacy of Anti-BCMA-GPRC5D CAR-T Cells Therapy in the Treatment of r/r MM". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06515262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*